Monday, October 14, 2024 from 2:15 PM to 3:45 PM MST at Convention Center North Building / Meeting Room 122
Available for 1.50 hours of CPE creditActivity Number: 0204-9999-24-254-L01Activity Type: An Application-Based ActivityAntibiotic resistance has increasingly become more common in clinical practice, with multidrug-resistant (MDR) gram-negative bacteria contributing to prolonged hospital stays, increased healthcare costs, and high mortality rates among adult and pediatric populations. Using complex and challenging real-world cases, this session will present clinical evidence supporting the newer and pipeline antibiotics to treat MDR gram-negative bacterial infections and evaluate recent literature and updates in gram-negative bacterial infection management. Attendees will learn to identify patient-specific risk factors for MDR gram-negative bacterial infections, interpret resistance patterns accurately, and understand the place in therapy of the newer antibiotics to select the most appropriate antibiotic and improve patient outcomes.
This activity is approved for Board Certified Pediatric Pharmacy Specialist (BCPPS) and Board Certified Crtical Care Pharmacist (BCCCP) recertification credit.
The BPPS/BCCCP Clinical Sessions are part of the professional development program for the recertification of board-certified Pediatric specialists and Critical Care pharmacists by the Board of Pharmacy Specialties and jointly provided by ACCP and the American Society of Health-System Pharmacists (ASHP). In order to earn the BCPPS/BCCCP recertification credit, participants must attend the session, claim the continuing pharmacy education credit, and pass the associated posttest. Access to the Clinical Sessions posttests will be available on December 18, 2024, at www.accp.com/myaccount to anyone who has purchased access to the BCPPS or BCCCP posttests. For participants who have not purchased access to the posttest, access can be purchased until 5:30 p.m. on Tuesday, October 15, at the ACCP Registration Desk. The deadline to submit posttests for these sessions will be December 16, 2025.
Learning Objectives1. Compare the spectrum of activity, pharmacokinetics, and pharmacodynamic properties of newly approved antibiotics for the treatment of difficult-to-treat gram-negative bacterial infections in adult and pediatric populations.
2. Interpret biomedical literature including study design and methodology, significance of reported data and conclusions, limitations, and applicability of study results to adult and pediatric patients with difficult-to-treat gram-negative bacterial infections.
3. Given a description of an adult or pediatric patient with a difficult-to-treat gram-negative infection, design an antibiotic regimen that reflects the application of the best available evidence and current guidelines.
 | | Speaker: | Trang D. Trinh, Pharm.D., MPH, BCIDP, BCPS | | Associate Professor of Clinical Pharmacy
University of California, San Francisco School of Pharmacy
San Francisco, CA
| | View Biography |
|
 | | Speaker: | Kalen B. Manasco, Pharm.D., FCCP, FPPA, BCPPS, BCPS | | Clinical Professor and Division Head
Department of Pharmacotherapy and Translational Research
University of Florida College of Pharmacy
Gainesville, Florida | | View Biography |
|